#USA #New York #Parkinson's Foundation #PD GENEration #PD Trial Navigator

Parkinson's Foundation Launches PD Trial Navigator to Propel Clinical Trials

On August 19, 2025, the Parkinson's Foundation unveiled its latest initiative, the PD Trial Navigator, designed to significantly advance clinical trials focused on the genetic aspects of Parkinson's disease (PD). This pilot program is a critical enhancement to the ongoing PD GENEration study, which has been pivotal in shaping our understanding of genetic links to Parkinson's disease. The primary goal of PD Trial Navigator is to facilitate participant engagement and expedite their enrollment in clinical trials that target genetic mutations related to Parkinson's.

Understanding PD GENEration

Since its inception, PD GENEration has successfully enrolled over 25,000 individuals living with Parkinson's, offering them insights into their genetic makeup and how it relates to their condition. As participants uncover their genetic associations with PD, they can actively engage in various clinical trials, effectively fast-tracking research towards new therapies and treatments.

Parkinson's Foundation President and CEO, John L. Lehr, emphasized the significance of this program, stating, "This pilot initiative represents a remarkable step forward in our international genetics study. We are not only providing genetic testing and counseling free of charge but also fostering community engagement in important research."

Overcoming Challenges in Clinical Trials

Genetic-focused clinical trials are critical as they investigate innovative therapies that could pave the way for treatments catered to specific genetic mutations associated with Parkinson's. However, these trials often face significant barriers, including funding limitations and challenges in participant recruitment. The PD Trial Navigator aims to address these obstacles by actively connecting with and guiding eligible participants from the PD GENEration study towards available clinical trials. Each trial must adhere to strict regulatory standards, involving FDA regulations and Institutional Review Board (IRB) approvals, ensuring participant safety throughout the process.

Dr. James Beck, executive vice president and chief scientific officer of the Parkinson's Foundation, highlighted the importance of widespread genetic testing, stating, "Our research has demonstrated that a greater number of individuals possess Parkinson's-related genetic variants than previously thought. This revelation underscores the necessity for more people to undergo genetic testing, thus broadening the pool of candidates for gene-targeted therapies."

The Role of PD Trial Navigator

The PD Trial Navigator program will provide education and guidance to participants, helping them navigate the clinical trial landscape while aligning their individual genetic profiles with active studies. As participants explore trials designed for their unique genetic variants, they gain an opportunity to partake in groundbreaking research efforts.

One participant, Daniel Rothschild, expressed his enthusiasm about this development, stating, "Having been involved in several research studies since my PD diagnosis, I now feel empowered with the knowledge from PD GENEration to focus on research tailored to my specific genetic mutation. I am hopeful that by engaging in this program, I can contribute to advancing crucial research that benefits not only myself but also others with a similar genetic background."

Continued Commitment to Research

The Parkinson's Foundation collaborates with numerous partners within the industry to compute findings that play a central role in solving the challenges associated with Parkinson's disease. For those interested in contributing to this clinical endeavor, the Foundation has made available a list of actively recruiting trials on their website.

Moreover, gratitude is extended to the Global Parkinson's Genetics Program (GP2), part of the Aligning Science Across Parkinson's (ASAP) initiative, for their support. Individuals keen to learn more about the PD GENEration program or to inquire about enrollment can contact the Foundation at 1-800-4PD-INFO (473-4636) or visit their online resources.

About the Parkinson's Foundation

Established in 1957, the Parkinson's Foundation is dedicated to enhancing the quality of life for individuals living with Parkinson's disease through extensive research and improved clinical care. With an investment exceeding $474 million in PD-specific research, the Foundation stands resilient in its mission to end Parkinson's disease while leveraging the collective strength of its global community. Connect with the Parkinson's Foundation through their platforms and contribute to the ongoing fight against this debilitating condition.